MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.87
-2.14
-4.86%
Closed 16:00 05/20 EDT
OPEN
44.09
PREV CLOSE
44.01
HIGH
44.52
LOW
39.36
VOLUME
500.94K
TURNOVER
14.11M
52 WEEK HIGH
102.00
52 WEEK LOW
38.02
MARKET CAP
867.24M
P/E (TTM)
-7.5886
1D
5D
1M
3M
1Y
5Y
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $45 From $70, Maintains Perform Rating
MT Newswires · 1d ago
Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.
Zacks · 1d ago
NeuroMetrix, Zealand Pharma top healthcare gainers; China SXT, Ocuphire lead losers' pack
Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceuticals (...
Seekingalpha · 1d ago
Sector Update: Health Care
MT Newswires · 2d ago
Enanta's stock is down after its experimental RSV treatment failed in a mid-stage clinical trial
Shares of Enanta Pharmaceuticals Inc. slid 19.3% in premarket trading on Thursday, the day after the company said its experimental treatment for respiratory syncytial virus did not meet the primary endpoint in a Phase 2b clinical trial. The therapy did not...
marketwatch.com · 2d ago
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 2d ago
Baird Adjusts Price Target on Enanta Pharmaceuticals to $90 From $130, Keeps Outperform Rating
MT Newswires · 2d ago
Top Premarket Decliners
MT Newswires · 2d ago
More
No Data
Learn about the latest financial forecast of ENTA. Analyze the recent business situations of Enanta Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

20.00%Strong Buy
30.00%Buy
40.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average ENTA stock price target is 66.56 with a high estimate of 103.00 and a low estimate of 35.00.
High103.00
Average66.56
Low35.00
Current 41.87
EPS
Actual
Estimate
-1.30-0.98-0.65-0.33
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 248
Institutional Holdings: 20.73M
% Owned: 100.08%
Shares Outstanding: 20.71M
TypeInstitutionsShares
Increased
61
1.07M
New
18
1.53M
Decreased
65
1.30M
Sold Out
30
521.45K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Bruce Carter
President/Chief Executive Officer/Director
Jay Luly
Chief Financial Officer/Senior Vice President - Finance
Paul Mellett
Senior Vice President/Chief Scientific Officer
Yat Sun Or
Senior Vice President/General Counsel
Nathaniel Gardiner
Senior Vice President
Tara Kieffer
Senior Vice President
Brendan Luu
Independent Director
Mark Foletta
Independent Director
Yujiro Hata
Independent Director
Kristine Peterson
Independent Director
Lesley Russell
Independent Director
Terry Vance
No Data
No Data
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in development of small molecule drugs for the treatment of viral infections and liver diseases. The Company has clinical candidates for the disease targets, including respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). The Company has discovered glecaprevir, a protease inhibitor discovered and developed for the treatment of chronic hepatitis C virus (HCV). Glecaprevir is co-formulated direct-acting antiviral (DAA), a combination treatment for HCV infection under the tradenames: MAVYRET and MAVIRET. Its product candidates also include EDP-514, EDP-305 and EDP-938. The Company's subsidiary is Enanta Pharmaceuticals Security Corporation.

Webull offers kinds of Enanta Pharmaceuticals Inc stock information, including NASDAQ:ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.